Labcorp Holdings Inc. (FRA:N6B)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Diagnostics (Dx) Revenue	10.88B	10.14B
Diagnostics (Dx) Revenue Growth	7.22%	7.75%
Biopharma Laboratory Services (BLS) Revenue	3.10B	2.92B
Biopharma Laboratory Services (BLS) Revenue Growth	6.01%	5.35%
Revenue (Other)	-23.00M	-58.00M
Revenue (Total)	13.95B	13.01B
Revenue (Total) Growth	7.25%	6.97%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Diagnostics (Dx) Operating Earnings	1.78B	1.61B
Diagnostics (Dx) Operating Earnings Growth	10.81%	0.94%
Biopharma Laboratory Services (BLS) Operating Earnings	498.50M	458.90M
Biopharma Laboratory Services (BLS) Operating Earnings Growth	8.63%	15.80%
Operating Income (Other)	-893.70M	-978.50M
Operating Income (Total)	1.38B	1.09B
Operating Income (Total) Growth	27.42%	49.77%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
North America % Total Revenue	-	87.00%
Europe % Total Revenue	-	9.00%
Other Geography % Total Revenue	-	4.00%
Organic Revenue Growth	4.40%	3.90%

Updated Dec 31, 2025. Data Source: Fiscal.ai.